RU2363696C2 - Производные нафтилена как ингибиторы цитохрома р450 - Google Patents

Производные нафтилена как ингибиторы цитохрома р450 Download PDF

Info

Publication number
RU2363696C2
RU2363696C2 RU2006103996/04A RU2006103996A RU2363696C2 RU 2363696 C2 RU2363696 C2 RU 2363696C2 RU 2006103996/04 A RU2006103996/04 A RU 2006103996/04A RU 2006103996 A RU2006103996 A RU 2006103996A RU 2363696 C2 RU2363696 C2 RU 2363696C2
Authority
RU
Russia
Prior art keywords
alkyl
alkenyl
halogen
ring
formula
Prior art date
Application number
RU2006103996/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2006103996A (ru
Inventor
Ванесса СМИТ (GB)
Ванесса Смит
Энтони НАЙГРО (US)
Энтони Найгро
Марк МАЛВИХИЛЛ (US)
Марк Малвихилл
Кара СЕСАРИО (US)
Кара Сесарио
Патришия Энн БЕК (US)
Патришия Энн Бек
Арлиндо Лукас КАСТЭЛАНО (US)
Арлиндо Лукас КАСТЭЛАНО
Original Assignee
Оси Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оси Фармасьютикалз, Инк. filed Critical Оси Фармасьютикалз, Инк.
Publication of RU2006103996A publication Critical patent/RU2006103996A/ru
Application granted granted Critical
Publication of RU2363696C2 publication Critical patent/RU2363696C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
RU2006103996/04A 2003-07-10 2004-07-12 Производные нафтилена как ингибиторы цитохрома р450 RU2363696C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48638203P 2003-07-10 2003-07-10
US60/486,382 2003-07-10

Publications (2)

Publication Number Publication Date
RU2006103996A RU2006103996A (ru) 2006-07-10
RU2363696C2 true RU2363696C2 (ru) 2009-08-10

Family

ID=34079229

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006103996/04A RU2363696C2 (ru) 2003-07-10 2004-07-12 Производные нафтилена как ингибиторы цитохрома р450

Country Status (15)

Country Link
EP (1) EP1654236A1 (no)
JP (1) JP4832295B2 (no)
KR (1) KR20060052799A (no)
CN (1) CN1819996B (no)
AU (1) AU2004257257B2 (no)
BR (1) BRPI0412424A (no)
CA (1) CA2532078A1 (no)
IL (1) IL172812A0 (no)
IS (1) IS8223A (no)
MX (1) MXPA06000401A (no)
NO (1) NO20060114L (no)
RU (1) RU2363696C2 (no)
SG (1) SG144941A1 (no)
UA (1) UA87822C2 (no)
WO (1) WO2005007631A1 (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014015137A2 (en) * 2012-07-18 2014-01-23 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1696899A1 (en) 2003-12-17 2006-09-06 Allergan, Inc. Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b
US7662844B2 (en) 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
JP6088425B2 (ja) 2010-06-01 2017-03-01 アンジオン バイオメディカ コーポレーション チトクロームｐ４５０阻害剤およびその使用
EP2638021B1 (en) * 2010-11-13 2018-09-26 Innocrin Pharmaceuticals, Inc. 1-(6,7-Bis(difluoromethoxy)naphthalen-2-yl)-2-methyl-1-(1H-1,2,3-triazol-4-yl)propan-1-ol as inhibitor of CYP17 for the treatment of androgen dependent diseases like prostate cancer
EA201390876A1 (ru) * 2010-12-13 2013-12-30 Вайамет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
CN102586187A (zh) * 2012-02-23 2012-07-18 深圳市中美康士生物科技有限公司 一种中性粒细胞体外保存方法及培养基
HUE055262T2 (hu) 2014-08-11 2021-11-29 Angion Biomedica Corp Citokróm P450 inhibitorok és ezek alkalmazásai
CN104523967B (zh) * 2014-12-12 2017-08-01 扬子江药业集团北京海燕药业有限公司 一种柏艾胶囊作为cyp酶抑制剂的应用
AU2015374231B2 (en) 2014-12-31 2020-07-23 Angion Biomedica Corp. Methods and agents for treating disease
GB201602572D0 (en) * 2016-02-12 2016-03-30 Eriksson Leif And Strid Ake And Sirsjö Allan New compound and uses
WO2018065288A1 (de) 2016-10-07 2018-04-12 Bayer Cropscience Aktiengesellschaft 2-[2-phenyl-1-(sulfonylmethyl)vinyl]-imidazo[4,5-b]pyridin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel im pflanzenschutz
EP3568392B1 (de) 2017-01-10 2021-02-24 Bayer Aktiengesellschaft Imidazol-derivate als schädlingsbekämpfungsmittel
KR20230020566A (ko) 2017-01-10 2023-02-10 바이엘 악티엔게젤샤프트 해충 방제제로서의 헤테로사이클 유도체

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291944A (no) * 1960-05-04
NL131915C (no) * 1966-07-27
DE3508903A1 (de) * 1985-03-13 1986-09-18 Hoechst Ag, 6230 Frankfurt Neue 3-pyridylmethylnaphtylderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3628545A1 (de) * 1985-09-23 1987-04-23 Hoechst Ag Arylmethylazole und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
AU5285593A (en) * 1992-10-21 1994-05-09 Sankyo Company Limited Azole compound
DE69924717T2 (de) * 1998-04-23 2006-03-09 Takeda Pharmaceutical Co. Ltd. Naphthalene derivate ,ihre herstellung und verwendung
JP4546589B2 (ja) * 1998-04-23 2010-09-15 武田薬品工業株式会社 ナフタレン誘導体
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
JP4520012B2 (ja) * 1999-10-22 2010-08-04 武田薬品工業株式会社 １−置換−１−（１ｈ−イミダゾール−４−イル）メタノール類

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Li X. et al, (1R,2S)-1-(6-Metoxy-2-naphthyl)-3-methyl-2-(p-methylphenylsulfonylamino)butan-1-ol. Acta Crystallographica, 2003, E59, стр.0706-0707. Wahler D. et al. Enzyme Fingerprints of Activity, and Stereo- and Enantioselectivity from Fluorogenic and Chromogenic Substrate Arrays. Chemistry European Journal, 2002, том 8, №14, стр.3211-3228. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014015137A2 (en) * 2012-07-18 2014-01-23 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
WO2014015137A3 (en) * 2012-07-18 2014-03-13 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases

Also Published As

Publication number Publication date
CA2532078A1 (en) 2005-01-27
AU2004257257A1 (en) 2005-01-27
JP4832295B2 (ja) 2011-12-07
KR20060052799A (ko) 2006-05-19
BRPI0412424A (pt) 2006-09-05
NO20060114L (no) 2006-02-09
UA87822C2 (ru) 2009-08-25
CN1819996B (zh) 2010-10-27
EP1654236A1 (en) 2006-05-10
CN1819996A (zh) 2006-08-16
MXPA06000401A (es) 2006-03-17
WO2005007631A1 (en) 2005-01-27
IL172812A0 (en) 2006-06-11
IS8223A (is) 2006-01-10
AU2004257257B2 (en) 2011-05-12
SG144941A1 (en) 2008-08-28
RU2006103996A (ru) 2006-07-10
JP2007523866A (ja) 2007-08-23

Similar Documents

Publication Publication Date Title
RU2363696C2 (ru) Производные нафтилена как ингибиторы цитохрома р450
EP2368887B1 (en) 1, 2, 3-triazole derivatives for use as stearoyl-coa desaturase inhibitors
CN101309912B (zh) 噁唑化合物和药物组合物
EP1988081B1 (en) Binding inhibitor of sphingosine-1-phosphate
AU777859B2 (en) N-substituted carbamoyloxyalkyl-azolium derivatives
HUT74450A (en) Anthranilic acid derivative and pharmaceutical compns. contg. such compds.
US6194446B1 (en) Hypoglycemic and hypolipidemic compounds
US7662844B2 (en) Naphthylene derivatives as cytochrome P450 inhibitors
CA2126972C (en) Styrene derivative and salts thereof
KR20010101730A (ko) 매트릭스 금속단백질분해효소 억제제로서의2,3,4,5-테트라하이드로-1에이치-[1,4]벤조디아제핀-3-하이드록삼산
JPH0592957A (ja) ２−置換キノリン類、それらの製造方法、並びに薬剤におけるそれらの使用
US20090203696A1 (en) Aryl- and Heteroaryl-Ethyl-Acylguanidine Derivatives, Their Preparation and Their Application in Therapeutics
JP2021102645A (ja) メプリンアルファ及びベータの新規な阻害剤
JPH0649033A (ja) 光学活性アゾール化合物およびその用途
CA2407463C (en) N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
WO2009034258A1 (fr) Derives de tri-amino-pyrimidine cyclobutenedione comme inhibiteurs de phosphatase cdc25
JPH0881443A (ja) 細胞外マトリックス金属プロテアーゼ阻害剤
WO2003031437A1 (en) Propylcarbamate derivatives as inhibitors of serine and cysteine proteases
WO2023177591A1 (en) Haloalkylpyridyl triazole mll1-wdr5 protein-protein interaction inhibitor
JP2005298333A (ja) 新規トリアゾール誘導体及びこれを有効成分とする抗真菌剤
JPH07157470A (ja) カルボスチリル誘導体

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20110713